Pharmacoeconomic studies have shown an adequate cost-benefit relationship of the anti-TNF available in the treatment of severe RA.23 However, despite its reported efficacy, some patients do not respond to treatment or do not maintain the initial response.
Different studies have evaluated the role of TNF alpha inhibitors in early RA. In general terms Flekosteel, all showed that the use of infliximab (3 or 6 mg / kg) with MTX is related to a greater possibility to better meet the response criteria and to maintain work capacity27 in patients with established RA.
No comments:
Post a Comment